Page last updated: 2024-12-05

n-phenylurea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6145
CHEMBL ID168445
CHEBI ID180992
SCHEMBL ID54471
MeSH IDM0584260

Synonyms (61)

Synonym
CHEBI:180992
1-phenylurea
phenylcarbamide
monophenylurea
stabilisator vh
stabilizer vh
64-10-8
n-phenylurea
urea, phenyl-
phenylurea
nsc2781
nsc-2781
inchi=1/c7h8n2o/c8-7(10)9-6-4-2-1-3-5-6/h1-5h,(h3,8,9,10
n-phenylurea, 97%
nsc 2781
einecs 200-576-5
ai3-15401
STK398254
AKOS000113517
CHEMBL168445
phenyl-urea
P0247
NCGC00255737-01
dtxsid8042507 ,
dtxcid6022507
tox21_301449
cas-64-10-8
PHU ,
ksc-294-042
KUC112459N
AKOS015995294
bdbm50377117
urea, n-phenyl-
unii-862i85399w
862i85399w ,
amino-n-phenylamide
carbamimidic acid, phenyl- (9ci)
173893-72-6
FT-0601827
n-phenylurea [mi]
phenylcarbamimidic acid
SCHEMBL54471
n'- phenyl urea
3-phenylurea
phenyl urea
carbamimidicacid,phenyl-(9ci)
W-104861
F1967-0960
urea, n-phenyl
n-phenylcarbamimidic acid
mfcd00007944
J-520000
C11241
n-phenylurea, vetec(tm) reagent grade, 97%
1,2-diacylglycerol-bile-pc-pool
CS-W017760
DS-15729
EN300-16741
AMY37406
Q27269694
n-phenylcarbamimidicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency51.55950.000714.592883.7951AID1259369
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency51.99010.001024.504861.6448AID743215
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)1,000.00000.03403.987110.0000AID331282
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1721838Inhibition of Pseudomonas aeruginosa PvdP tyrosinase2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Development of phenylthiourea derivatives as allosteric inhibitors of pyoverdine maturation enzyme PvdP tyrosinase.
AID1721839Inhibition of Pseudomonas aeruginosa PvdP tyrosinase up to 100 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Development of phenylthiourea derivatives as allosteric inhibitors of pyoverdine maturation enzyme PvdP tyrosinase.
AID331282Inhibition of mushroom tyrosinase2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation.
AID331283Inhibition of melanin production in mouse B16 cells at 100 uM2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation.
AID457971Inhibition of alpha-MSH-induced melanin production in mouse B16 cells at 100 uM after 72 hrs2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Evaluation of 3,4-dihydroquinazoline-2(1H)-thiones as inhibitors of alpha-MSH-induced melanin production in melanoma B16 cells.
AID494973Antimelanogenic activity in mouse B16 cells assessed as inhibition of alpha-MSH-induced melanogenesis at 100 uM2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Refinement of the pharmacophore of 3,4-dihydroquinazoline-2(1H)-thiones for their anti-melanogenesis activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (36.84)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's6 (31.58)24.3611
2020's5 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.35 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]